OncoMatch/Clinical Trials/NCT05020444
TriPRIL CAR T Cells in Multiple Myeloma
Is NCT05020444 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including TriPRIL CAR T Cells and Cyclophosphamide for multiple myeloma.
Treatment: TriPRIL CAR T Cells · Cyclophosphamide · Fludarabine — This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Must have received: IMiD
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Must have received: anti-CD38 antibody
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Cannot have received: systemic therapy
Any prior systemic treatment for multiple myeloma within the 14 days prior to scheduled leukapheresis unless discussed with the medical monitor
Cannot have received: systemic steroid therapy
Exception: ≤10 mg prednisone or equivalent allowed
Receiving high-dose (e.g., >10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Cannot have received: immunosuppressive therapy
any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Cannot have received: autologous stem cell transplantation
Autologous stem cell transplantation within 3 months prior to leukapheresis
Cannot have received: allogeneic stem cell transplantation
Any prior allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy
Other CAR-T cell therapy within 6 months of leukapheresis
Cannot have received: bispecific T cell engager
No Bispecific T cell engagers within 6 months of apheresis
Cannot have received: (bendamustine)
No bendamustine within 6 months of apheresis
Lab requirements
Blood counts
ANC ≥1.0k/μl, PLT ≥50k/μl (no platelet transfusion within 7 days; no neupogen within 7 days, neulasta within 14 days)
Kidney function
Creatinine clearance ≥30 mL/min and not on dialysis
Liver function
AST/ALT <3 x ULN; Direct bilirubin <1.5 x ULN (allow x 3 ULN for Gilbert's syndrome)
Cardiac function
LVEF ≥40% by ECHO or MUGA scan
Adequate organ and marrow function as defined below: O2 saturation ≥92% on room air while awake; LVEF ≥40% by ECHO or MUGA scan; ANC ≥1.0k/μl, PLT ≥50k/μl, (NOTE: Platelet transfusion not allowed within 7 days; growth factor neupogen not allowed within 7 days, neulasta within 14 days); Creatinine clearance ≥30 mL/min and not on dialysis; AST/ALT <3 x ULN; Direct bilirubin <1.5 x ULN (allow x 3 ULN for Gilbert's syndrome); PTT, PT/INR <1.5 x ULN, unless on a stable dose of anti-coagulant for a thromboembolic event
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify